These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28898237)

  • 1. Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients.
    Gabasa M; Ikemori R; Hilberg F; Reguart N; Alcaraz J
    Br J Cancer; 2017 Oct; 117(8):1128-1138. PubMed ID: 28898237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant TIMP-1 production in tumor-associated fibroblasts drives the selective benefits of nintedanib in lung adenocarcinoma.
    Duch P; Díaz-Valdivia N; Gabasa M; Ikemori R; Arshakyan M; Fernández-Nogueira P; Llorente A; Teixido C; Ramírez J; Pereda J; Chuliá-Peris L; Galbis JM; Hilberg F; Reguart N; Radisky DC; Alcaraz J
    Cancer Sci; 2024 May; 115(5):1505-1519. PubMed ID: 38476010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic
    Ikemori R; Gabasa M; Duch P; Vizoso M; Bragado P; Arshakyan M; Luis IC; Marín A; Morán S; Castro M; Fuster G; Gea-Sorli S; Jauset T; Soucek L; Montuenga LM; Esteller M; Monsó E; Peinado VI; Gascon P; Fillat C; Hilberg F; Reguart N; Alcaraz J
    Cancer Res; 2020 Jan; 80(2):276-290. PubMed ID: 31694906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant TIMP-1 overexpression in tumor-associated fibroblasts drives tumor progression through CD63 in lung adenocarcinoma.
    Duch P; Díaz-Valdivia N; Ikemori R; Gabasa M; Radisky ES; Arshakyan M; Gea-Sorlí S; Mateu-Bosch A; Bragado P; Carrasco JL; Mori H; Ramírez J; Teixidó C; Reguart N; Fillat C; Radisky DC; Alcaraz J
    Matrix Biol; 2022 Aug; 111():207-225. PubMed ID: 35787446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D collagen migration patterns reveal a SMAD3-dependent and TGF-β1-independent mechanism of recruitment for tumour-associated fibroblasts in lung adenocarcinoma.
    Juste-Lanas Y; Díaz-Valdivia N; Llorente A; Ikemori R; Bernardo A; Arshakyan M; Borau C; Ramírez J; Ruffinelli JC; Nadal E; Reguart N; García-Aznar JM; Alcaraz J
    Br J Cancer; 2023 Apr; 128(6):967-981. PubMed ID: 36572730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix stiffening and β1 integrin drive subtype-specific fibroblast accumulation in lung cancer.
    Puig M; Lugo R; Gabasa M; Giménez A; Velásquez A; Galgoczy R; Ramírez J; Gómez-Caro A; Busnadiego Ó; Rodríguez-Pascual F; Gascón P; Reguart N; Alcaraz J
    Mol Cancer Res; 2015 Jan; 13(1):161-73. PubMed ID: 25280968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
    Dhillon S
    Target Oncol; 2015 Jun; 10(2):303-10. PubMed ID: 25894578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
    Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
    Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterotypic paracrine signaling drives fibroblast senescence and tumor progression of large cell carcinoma of the lung.
    Lugo R; Gabasa M; Andriani F; Puig M; Facchinetti F; Ramírez J; Gómez-Caro A; Pastorino U; Fuster G; Almendros I; Gascón P; Davalos A; Reguart N; Roz L; Alcaraz J
    Oncotarget; 2016 Dec; 7(50):82324-82337. PubMed ID: 27384989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.
    Reck M; Mellemgaard A; von Pawel J; Gottfried M; Bondarenko I; Cheng Y; Zarogoulidis K; Luft A; Bennouna J; Barrueco J; Aboshady H; Hocke J; Kaiser R; Douillard JY;
    Lung Cancer; 2015 Nov; 90(2):267-73. PubMed ID: 26415992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.
    Popat S; Mellemgaard A; Fahrbach K; Martin A; Rizzo M; Kaiser R; Griebsch I; Reck M
    Future Oncol; 2015; 11(3):409-20. PubMed ID: 25478720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.
    Gottfried M; Bennouna J; Bondarenko I; Douillard JY; Heigener DF; Krzakowski M; Mellemgaard A; Novello S; Orlov S; Summers Y; von Pawel J; Stöhr J; Kaiser R; Reck M
    Target Oncol; 2017 Aug; 12(4):475-485. PubMed ID: 28702806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nintedanib inhibits TGF-β-induced myofibroblast transdifferentiation in human Tenon's fibroblasts.
    Lin X; Wen J; Liu R; Gao W; Qu B; Yu M
    Mol Vis; 2018; 24():789-800. PubMed ID: 30636861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer.
    Syrios J; Nintos G; Georgoulias V
    Expert Rev Anticancer Ther; 2015; 15(8):875-84. PubMed ID: 26204906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report.
    Espinosa Bosch M; Asensi Diez R; García Agudo S; Clopes Estela A
    Farm Hosp; 2016 Jun; 40(4):316-27. PubMed ID: 27571499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma.
    Metzenmacher M; Rizzo F; Kambartel K; Panse J; Schaufler D; Scheffler M; Azeh I; Hoiczyk M; Turki AT; Atz J; Buchner H; Hoffmann C; C Christoph D
    Future Oncol; 2021 Oct; 17(30):3965-3976. PubMed ID: 34287064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
    Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
    J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.
    Corral J; Majem M; Rodríguez-Abreu D; Carcereny E; Cortes ÁA; Llorente M; López Picazo JM; García Y; Domine M; López Criado MP
    Clin Transl Oncol; 2019 Sep; 21(9):1270-1279. PubMed ID: 30771085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.
    Hilberg F; Tontsch-Grunt U; Baum A; Le AT; Doebele RC; Lieb S; Gianni D; Voss T; Garin-Chesa P; Haslinger C; Kraut N
    J Pharmacol Exp Ther; 2018 Mar; 364(3):494-503. PubMed ID: 29263244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts.
    Vizoso M; Puig M; Carmona FJ; Maqueda M; Velásquez A; Gómez A; Labernadie A; Lugo R; Gabasa M; Rigat-Brugarolas LG; Trepat X; Ramírez J; Moran S; Vidal E; Reguart N; Perera A; Esteller M; Alcaraz J
    Carcinogenesis; 2015 Dec; 36(12):1453-63. PubMed ID: 26449251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.